DC_regs protect mice from the incidence and severity of cutaneous cGVHD. (A,B) The irradiated recipient BALB/c mice (10 per group) received transplants of T-cell-depleted BM cells and CD4⁺CD25⁻ T cells obtained from B10.D2 mice and were then treated with or without the recipient-type mDCs, DC_regs, or RAPA after the transplantation. The incidence (A) and severity (B) of cutaneous cGVHD were monitored for 120 days after the transplantation. (C,D) The irradiated recipient BALB/c mice (10 per group) received T-cell-depleted BM cell and CD4⁺CD25⁻ T cell transplants obtained from B10.D2 mice, and were then treated with or without the recipient-type DC_regs after the disease onset. The incidence (C) and severity (D) of cutaneous cGVHD were monitored for 120 days after the transplantation. (E,F) The irradiated recipient BALB/c mice (10 per group) received T-cell-depleted BM cells and CD4⁺CD25⁻ T cells obtained from B10.D2 mice, and were then treated with or without the recipient-type DC_regs in combination with control Ig or anti-CD25 mAb. The incidence (E) and severity (F) of cutaneous cGVHD were monitored for 45 days after the transplantation. (G,H) CD4⁺CD25⁺ T cells (obtained from B10.D2 mice or the mice who received transplants), T-cell-depleted BM cells, and CD4⁺CD25⁻ T cells (obtained from B10.D2 mice) were transplanted into the irradiated recipient BALB/c mice (10 per group). The incidence (G) and severity (H) of cutaneous cGVHD were monitored for 45 days after the transplantation. *P < .01 compared with the untreated recipient mice by the log-rank test. Two replicate experiments with similar results were pooled.